SRT1720 kinase inhibitor product blog
Tags: Kinase Inhibitor; SRT1720; SRT1720 kinase inhibitor;
The SRT1720 n/a (Catalog #MBS8506166) is an Inhibitor and is intended for research purposes only. The product is available for immediate purchase.To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given inhibitor. We\'ve tested the SRT1720 with the following immunoassay(s):
Testing Data
SRT1720 is a selective activator of human SIRT1 (EC1.5 = 0.16 muM and maximum activation = 781%) versus the closest sirtuin homologues, SIRT2 and SIRT3, (SIRT2: EC1.5 = 37 muM; SIRT3: EC1.5 > 300 muM). This agent binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. [1] SRT1720 exhibited a pharmacokinetic profile suitable for in vivo evaluation in both mouse (bioavailability = 50%, terminal t1/2 = ~5 h, Area Under the Curve (AUC) = 7, 892 ng h-1 ml-1) and rat (bioavailability = 25%, terminal t1/2 = ~8.4 h, AUC = 3, 714 ng h-1 ml-1). [1] In diet-induced obese and genetically obese mice, SRT1720 improved insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes. [1] However, the claim that SRT-1720 is a SIRT1 activator has been questioned. [2, 3].
Solubility: DMSO >=101mg/mL - Water >=23mg/mL - Ethanol <1mg/mL. Formula: C25H23N7OS.HCl
CAS Number: 1001645-58-4.